|

IBI362 Clinical Trials

1 actively recruiting trial

▼ -1 trial since May 2026

Pipeline

Phase 2: 1

Top Sponsors

  • Innovent Biologics (Suzhou) Co. Ltd.1

Indications

  • Heart Failure With Preserved Ejection Fraction (HFPEF)1
  • Heart Failure With Mildly Reduced Ejection Fraction1
  • Heart Disease1
  • Obesity1

Other1 trial

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.